Fate Therapeutics Inc (NASDAQ:FATE) – Analysts at Wedbush issued their FY2022 earnings per share estimates for shares of Fate Therapeutics in a research note issued to investors on Thursday, according to Zacks Investment Research. Wedbush analyst D. Nierengarten anticipates that the biopharmaceutical company will post earnings of $0.90 per share for the year. Wedbush currently has a “Outperform” rating and a $7.00 target price on the stock.
A number of other brokerages also recently commented on FATE. ValuEngine raised shares of Fate Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Zacks Investment Research downgraded shares of Fate Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, January 22nd. BidaskClub raised shares of Fate Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Tuesday, January 23rd. HC Wainwright reaffirmed a “buy” rating on shares of Fate Therapeutics in a report on Thursday, November 2nd. Finally, BMO Capital Markets reaffirmed a “buy” rating and issued a $7.00 price target on shares of Fate Therapeutics in a report on Thursday, November 2nd. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Fate Therapeutics currently has an average rating of “Buy” and a consensus price target of $7.71.
A number of institutional investors have recently bought and sold shares of the stock. The Manufacturers Life Insurance Company raised its position in Fate Therapeutics by 61.4% in the 4th quarter. The Manufacturers Life Insurance Company now owns 33,337 shares of the biopharmaceutical company’s stock worth $203,000 after purchasing an additional 12,686 shares during the period. Raymond James & Associates purchased a new stake in Fate Therapeutics in the 4th quarter worth about $141,000. Hochman Cole Investment Advisors Inc. purchased a new stake in Fate Therapeutics in the 3rd quarter worth about $158,000. New York State Common Retirement Fund purchased a new stake in Fate Therapeutics in the 2nd quarter worth about $131,000. Finally, Rhumbline Advisers purchased a new stake in Fate Therapeutics in the 2nd quarter worth about $133,000. 50.00% of the stock is currently owned by institutional investors.
Fate Therapeutics Company Profile
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.